Nobori Dual Antiplatelet Therapy as Appropriate Duration
Nobori Dual Antiplatelet Therapy as Appropriate Duration.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Tokyo
-
Minato-ku, Tokyo, Japan, 105-0013
- Non-profit organization Associations for Establishment of Evidence in Interventions
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects > 20 years old
- Undergoing percutaneous intervention with Nobori deployment
- No contraindication to prolonged DAPT
Exclusion Criteria:
- Subjects absolutely necessitating continuous DAPT
- Planned surgery necessitating discontinuation of antiplatelet therapy after enrollment.
- Active pathological bleeding
- Status of cardiogenic shock at enrollment
- Pregnant women
- Life expectancy of < 1.5 years
- Subjects unable to give informed consent
- Episode of stroke < 6 months
- Subjects with allergies or hypersensitivity to material of coating, Biolimus A9, and antiplatelet drugs.
- Subjects treated with other kind of DES or BMS during the index procedure
- Previous intervention with DES < 6 months.
- Study participation impractical per investigator judgment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Short-term DAPT (6 months) group
6 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
|
Subjects randomized 6 month DAPT will be prescribed either aspirin or thienopyridine (clopidogrel or ticlopidine) following 6 months DAPT for the duration of study, which is left on the physician's discretion.
|
|
Experimental: Long-term DAPT (18 months) group
18 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
|
Subjects randomized 18 month DAPT will be prescribed both aspirin and thienopyridine (clopidogrel or ticlopidine) for 18 month after stenting.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Net adverse clinical and cerebral event (NACCE)
Time Frame: 18 months
|
NACCE include all-cause death, non-fatal myocardial infarction, cerebrovascular events, and major bleeding.
|
18 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
All-cause death
Time Frame: 18 months
|
18 months
|
|
Non-fatal myocardial infarction
Time Frame: 18 months
|
18 months
|
|
Cerebrovascular events
Time Frame: 18 months
|
18 months
|
|
Major bleeding
Time Frame: 18 months
|
18 months
|
|
Rate of target lesion revascularization
Time Frame: 18 months
|
18 months
|
|
Minor bleeding
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Coronary Artery Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Aspirin
Other Study ID Numbers
Other Study ID Numbers
- NIPPON 5.0
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.